Immatics

Immatics EBITDA per Share

The EBITDA per Share of Immatics (IMTX) as of Nov 16, 2026 is -1.44 EUR. In the previous year, EBITDA per Share was -0.28 EUR — a change of 417.36% (lower).

EBITDA per Share

-1.44EUR

YoY

417.36%

Last updated:

EBITDA per Share of Immatics is 2025 -1.44 EUR. EBITDA per Share of Immatics was 2024 -0.28 EUR. It decreases by 417.36% lower compared to the previous year.

The Immatics EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
-0.51 EUR
Jan 1, 2019
-0.49 EUR
Jan 1, 2020
-1.07 EUR
Jan 1, 2021
-1.33 EUR
Jan 1, 2022
0.44 EUR
Jan 1, 2023
-1.16 EUR
Jan 1, 2024
-0.28 EUR
Jan 1, 2025
-1.44 EUR
The Immatics EBITDA per Share history
YEAREBITDA per ShareYoY
-1.44EUR+417.36%
-0.28EUR-75.93%
-1.16EUR-362.72%
0.44EUR-133.22%
-1.33EUR+23.77%
-1.07EUR+117.01%
-0.49EUR-3.41%
-0.51EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Immatics Stock analysis

What does Immatics do? Immatics NV develops T cell receptor-based immunotherapies for cancer treatment, focusing on solid tumors through Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). The company's pipeline includes eight therapeutic programs, with four in clinical trials: IMA201 (MAGEA4/8), IMA202 (MAGEA1), ACTolog IMA 101 (Multi-target pilot trial), and IMA203 (PRAME). Four programs are in preclinical development, such as IMA204 (COL6A3) and IMA401 (Cancer testis antigen). Immatics generates revenue through licensing agreements and potential future sales of its therapies, targeting pharmaceutical companies and research institutions seeking advanced cancer treatments. The company's clinical-stage therapies are designed to enable robust T-cell responses against cancer targets, with programs like IMA201 and IMA202 focused on solid tumors. IMA203 addresses both hematological and solid cancers, while preclinical programs like IMA401 and IMA402 target cancer testis antigens. Immatics partners with biopharmaceutical firms to advance its pipeline, leveraging its TCR technology platform to develop therapies for unmet medical needs in oncology. Immatics' revenue model relies on strategic partnerships and licensing deals with pharmaceutical companies, which fund clinical development and gain access to its proprietary TCR platform. The firm's focus on solid tumors and hematological cancers attracts interest from major biopharmaceutical players looking to expand their oncology portfolios. Through its eight therapeutic programs, Immatics aims to deliver innovative treatments that address high unmet medical needs in cancer therapy. Immatics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Immatics stock

EBITDA per Share of Immatics is -1.44 EUR in 2025.

EBITDA per Share of Immatics changed from -0.28 EUR to -1.44 EUR, representing a 417.36% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Immatics since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Immatics

All Key Metrics — Immatics